CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and GlaxoSmithKline (GSK), announced today that they have chosen BIO Ventures for Global Health (BVGH) to administer an Intellectual Property (IP) Pool that was established in February 2009. The IP Pool was formed to aid in the discovery and development of new medicines for the treatment of certain neglected tropical diseases, defined by the U.S. Food and Drug Administration (FDA), in the world’s least developed countries. By adopting a more accessible approach to IP, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases.
